Successful Treatment of <i>Candida auris</i> Ventriculitis With Intravenous Liposomal Amphotericin B and Oral Flucytosine: A Case Report

<i>Candida auris</i> is a rapidly emerging fungal pathogen associated with high resistance rates, particularly in healthcare settings. It most commonly affects patients with severe underlying medical conditions and requiring complex medical care. Patients with invasive medical devices tend to be at increased risk for getting <i>C auris</i> and developing infection. This article presents a case of <i>C auris</i> ventriculitis successfully treated with intravenous liposomal amphotericin B and oral flucytosine. A 41-year-old man with multiple comorbidities, including recent placement of a ventriculoperitoneal shunt, presented with suspected sepsis. <i>Candida auris</i> was isolated from cerebrospinal fluid cultures. Antifungal therapy along with removal of the shunt led to resolution of infection without complications. This case highlights the challenges posed by <i>C auris</i> infections and underscores the importance of appropriate treatment strategies.